The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study (vol 12, e0175207, 2017)



Moots, Robert J ORCID: 0000-0001-7019-6211, Xavier, Ricardo M, Mok, Chi Chiu, Rahman, Mahboob U, Tsai, Wen-Chan, Al-Maini, Mustafa H, Pavelka, Karel, Mahgoub, Ehab, Kotak, Sameer, Korth-Bradley, Joan
et al (show 4 more authors) (2017) The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study (vol 12, e0175207, 2017). PLOS ONE, 12 (6).

Access the full-text of this item by clicking on the Open Access link.
Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 19 Jun 2017 06:21
Last Modified: 02 Apr 2021 08:25
DOI: 10.1371/journal.pone.0179308
Open Access URL: http://journals.plos.org/plosone/article?id=10.137...
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3008031